INMD Stock Analysis: InMode | NASDAQ
Medical Devices | NASDAQ, USA | Market Cap: 823m USD | 12M Return: -7% | IL0011595993 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.02M
EPS Trend: -96.4%
Qual. Beats: 0
Rev. Trend: -92.1%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
InMode Ltd. is an Israel-based medical device company that designs, manufactures, and markets minimally invasive and non-invasive aesthetic medical products built around its proprietary radio frequency (RF) technologies, including RF-assisted lipolysis and deep subdermal fractional RF. The medical aesthetics segment is a consumer-driven sub-sector within healthcare equipment, fueled by demand for non-surgical cosmetic procedures.
The companys product portfolio spans liposuction with simultaneous skin tightening, body and face contouring, ablative skin rejuvenation, womens health applications, hair reduction, wrinkle and cellulite treatment, and hands-free platforms for skin tightening, fat reduction, and muscle stimulation.
InMode distributes its products through third-party distributors across 15 countries, including the United States, Canada, the United Kingdom, Ireland, Spain, Portugal, France, Belgium, Luxembourg, Italy, Germany, Austria, Japan, Australia, and India. The company was founded in 2008, originally as Invasix Ltd., and rebranded to InMode Ltd. in November 2017. It is headquartered in Yokneam, Israel.
- US demand for minimally invasive aesthetic procedures drives core revenue growth
- International sales in Asia and Europe outpace domestic segment growth
- Strong free cash flow funds elevated dividends and ongoing share repurchases
| Net Income: 77.5m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA -2.57 > 1.0 |
| NWC/Revenue: 152.3% < 20% (prev 142.5%; Δ 9.80% < -1%) |
| CFO/TA 0.12 > 3% & CFO 88.6m > Net Income 77.5m |
| Net Debt (-496.7m) to EBITDA (84.2m): -5.90 < 3 |
| Current Ratio: 8.18 > 1.5 & < 3 |
| Outstanding Shares: last quarter (59.4m) vs 12m ago -6.69% < -2% |
| Gross Margin: 76.52% > 18% (prev 79.98%; Δ -3.46% > 0.5%) |
| Asset Turnover: 52.44% > 50% (prev 56.69%; Δ -4.25% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.79 (Total Current Assets 650.0m - Total Current Liabilities 79.4m) / Total Assets 720.3m |
| B: 1.34 (Retained Earnings 968.5m / Total Assets 720.3m) |
| C: 0.12 (EBIT TTM 83.5m / Avg Total Assets 714.3m) |
| D: 6.90 (Book Value of Equity 629.1m / Total Liabilities 91.2m) |
| Altman-Z'' = 17.61 = AAA |
| DSRI: 1.38 (Receivables 77.2m/60.0m, Revenue 374.6m/401.6m) |
| GMI: 1.05 (GM 79.98% / 76.52%) |
| AQI: 1.00 (AQ_t 0.08 / AQ_t-1 0.08) |
| SGI: 0.93 (Revenue 374.6m / 401.6m) |
| TATA: -0.02 (NI 77.5m - CFO 88.6m) / TA 720.3m) |
| Beneish M = -2.72 (Cap -4..+1) = A |
As of October 17, 2026, the stock is trading at USD 14.16 with a total of 417,144 shares traded. Over the past week, the price has changed by -0.35%, over one month by -2.88%, over three months by -9.20% and over the past year by -6.96%.
Current recommended Stop Loss: 13.60 (which is 4% or 3.1 ATR below the current price).
InMode has received a consensus analysts rating of 3.00. Therefore, it is recommended to hold INMD.
- StrongBuy: 0
- Buy: 0
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 16.2 | 14.2% |
P/E Trailing = 11.8182
P/E Forward = 9.99
P/S = 2.1965
P/B = 1.2979
P/EG = 2.9004
Revenue TTM = 374.6m USD
EBIT TTM = 83.5m USD
EBITDA TTM = 84.2m USD
Long Term Debt = unknown (none)
Short Term Debt = 3.22m USD (from shortTermDebt, last fiscal year)
Debt = 4.45m USD (from shortLongTermDebtTotal, last quarter) (leases 4.45m already included)
Net Debt = -496.7m USD (calculated: Debt 4.45m - CCE 501.1m)
Enterprise Value = 326.2m USD (822.9m + Debt 4.45m - CCE 501.1m)
Interest Coverage Ratio = unknown (Ebit TTM 83.5m / Interest Expense TTM 0.0)
EV/FCF = 3.73x (Enterprise Value 326.2m / FCF TTM 87.5m)
FCF Yield = 26.81% (FCF TTM 87.5m / Enterprise Value 326.2m)
FCF Margin = 23.34% (FCF TTM 87.5m / Revenue TTM 374.6m)
Net Margin = 20.69% (Net Income TTM 77.5m / Revenue TTM 374.6m)
Gross Margin = 76.52% ((Revenue TTM 374.6m - Cost of Revenue TTM 87.9m) / Revenue TTM)
Gross Margin QoQ = 74.82% (prev 75.05%)
Tobins Q-Ratio = 0.45 (Enterprise Value 326.2m / Total Assets 720.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 4.45m)
Taxrate = 14.77% (13.4m / 91.0m)
NOPAT = 71.2m (EBIT 83.5m * (1 - 14.77%))
Current Ratio = 8.18 (Total Current Assets 650.0m / Total Current Liabilities 79.4m)
Debt / Equity = 0.01 (Debt 4.45m / totalStockholderEquity, last quarter 629.1m)
Debt / EBITDA = -5.90 (Net Debt -496.7m / EBITDA 84.2m)
Debt / FCF = -5.68 (Net Debt -496.7m / FCF TTM 87.5m)
Total Stockholder Equity = 656.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.85% (Net Income 77.5m / Total Assets 720.3m)
RoE = 11.80% (Net Income TTM 77.5m / Total Stockholder Equity 656.7m)
RoCE = 13.03% (EBIT 83.5m / Capital Employed (Total Assets 720.3m - Current Liab 79.4m))
RoIC = 11.38% (NOPAT 71.2m / Invested Capital 625.4m)
WACC = 8.43% (E(822.9m)/V(827.3m) * Re(8.48%) + D(4.45m)/V(827.3m) * Rd(0.0%) * (1-Tc(0.15)))
Discount Rate = 8.48% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.24 | Cagr: -15.16%
[DCF] Terminal Value 72.78% ; FCFF base≈94.1m ; Y1≈82.6m ; Y5≈66.7m
[DCF] Fair Price = 26.98 (EV 1.06b - Net Debt -496.7m = Equity 1.55b / Shares 57.5m; r=8.43% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -96.40 | EPS CAGR: -20.54% | SUE: -0.66 | # QB: 0
Revenue Correlation: -92.09 | Revenue CAGR: -10.65% | SUE: 0.29 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.32 | Chg30d=-4.73% | Revisions=-50% | Analysts=5
EPS current Year (2026-12-31): EPS=1.30 | Chg30d=-1.97% | Revisions=-29% | GrowthEPS=-19.0% | GrowthRev=-0.1%
EPS next Year (2027-12-31): EPS=1.37 | Chg30d=-5.25% | Revisions=-57% | GrowthEPS=+5.9% | GrowthRev=+2.3%
[Analyst] Revisions Ratio: -64% (up=1, down=10)